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Abstract: Arterial stiffness and central hemodynamics attract increasing scientific interest within the hypertensive com-
munity during the last decade. Accumulating evidence indicates that aortic stiffness is a strong and independent predictor 
of cardiovascular events and all-cause mortality in hypertensive patients, and its predictive value extends beyond tradi-
tional risk factors. The role of central hemodynamics and augmentation index (a marker of reflected waves), remains less 
established and requires further investigation. Several lines of evidence indicate that antihypertensive therapy results in 
significant reductions of pulse wave velocity and central hemodynamics. However, beta-blockers seem to be the only ex-
ception with significant within-class differences. Conventional beta-blockers, although equally effective in reducing pulse 
wave velocity, seem to be less beneficial on central hemodynamics and augmentation index than the other antihyperten-
sive drug categories, whereas the newer vasodilating beta-blockers seem to share the benefits of the other antihypertensive 
drugs. In conclusion, aortic stiffness seems ready for ‘prime-time’ in the management of essential hypertension, while fur-
ther research is needed for central hemodynamics and augmentation index.  
Keywords: Arterial stiffness, pulse wave velocity, augmentation index, central hemodynamics, aortic blood pressure, anti-
hypertensive drugs, beta-blockers. 
INTRODUCTION 
Aortic stiffness is considered the most important patho-
physiologic mechanism mediating pulse pressure increase 
and isolated systolic hypertension with ageing. The carotid-
femoral pulse wave velocity is a non-invasive method for the 
measurement of aortic stiffness and is currently considered 
the ‘gold standard’ for the evaluation of arterial elasticity. 
Central hemodynamics have attracted wide scientific interest 
during the last decade, due to the recognition that peripheral 
and central blood pressure may differ and that it is the cen-
tral blood pressure that imposes the load in the heart, brain, 
and the kidneys. 
According to the recent 2013 guidelines of the European 
Society of Hypertension/European Society of Cardiology for 
the management of arterial hypertension, the evaluation of 
carotid-femoral pulse wave velocity should be considered in 
hypertensive patients to detect large artery stiffening, and 
this recommendation is based on IIa-B level of evidence [1]. 
In contrast, the role of central hemodynamics is not yet es-
tablished, and the guidelines recognize the pathophysiologi-
cal, pharmacological, and therapeutical interest, but ac-
knowledge the need for further investigation before recom-
mending the evaluation of this parameter in everyday clinical 
practice [1].  
From the clinical point of view, it is important for the 
practicing physician to know whether aortic stiffness and 
central hemodynamics possess a strong predictive value for  
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cardiovascular events and all-cause mortality, whether the 
predictive value extends beyond traditional cardiovascular 
risk factors, whether the various antihypertensive drugs 
classes exert different effects on these parameters, and 
whether within-class differences exist in antihypertensive 
drug classes. The current review aims to critically evaluate 
existing literature in this topic and provide clinically mean-
ingful information.  
PHYSIOLOGY AND PATHOPHYSIOLOGY OF AR-
TERIAL STIFFNESS 
The pressure waveform is the summation of the forward 
wave, originating from left ventricular ejection, moving from 
the aorta to the periphery, and the backward wave, originat-
ing from the reflection of the descending wave to the periph-
ery, mainly at the level of resistance arteries. 
In younger age and health, the large conduit arteries (like 
the aorta) preserve their elasticity and the waveform travels 
with relatively slow velocity towards the periphery. There-
fore, the reflected wave meets the forward wave in diastole, 
resulting in increased diastolic central pressure and thus fa-
cilitating coronary perfusion. 
Ageing and disease (such as hypertension and other dis-
ease conditions) are associated with arterial stiffening, which 
in turn results in acceleration of the wave movement. There-
fore, the reflected wave meets the descending wave during 
systole, resulting in increased systolic central pressure and 
rather decreased diastolic central pressure, thus compromis-
ing coronary perfusion. 
From the above mentioned physiological and patho-
physiological mechanisms, it can be concluded that the 
76    The Open Hypertension Journal, 2013, Volume 5 Doumas et al. 
evaluation of the waveforms in two different sites of the arte-
rial tree (usually the carotid and femoral or radial artery) 
permits for the non-invasive estimation of pulse wave veloc-
ity (a measure of arterial stiffness), the augmentation index 
(a measure of the reflected wave), and central blood pres-
sure. The augmentation index is the ratio of augmentation 
pressure to pulse pressure, with the augmentation pressure 
representing the difference between the systolic pressure and 
the inflection peak.  
Several devices have been developed during the last 
years for the non-invasive estimation of these parameters, 
with Sphygmocor and Complior being the most widely used. 
It has to be admitted that invasive methods represent he 
gold-standard for the accurate and precise measurement of 
central hemodynamics and arterial stiffness. However, inva-
sive methods cannot be used in everyday clinical practice, 
and thus the non-invasive evaluation of central hemodynam-
ics and arterial stiffness has prevailed.  
CENTRAL HEMODYNAMICS 
Central blood pressure is the blood pressure at the proxi-
mal segment of the aorta and is currently considered more 
relevant than the peripheral blood pressure from a physio-
logical point of view, since: a) central systolic blood pressure 
is the pressure that the heart has to overcome at each systole, 
in order to maintain blood flow all over the organism, and 
thus a major contributor to the development of left ventricu-
lar hypertrophy in hypertension, b) central diastolic blood 
pressure is the main determinant of coronary perfusion, and 
c) central blood pressure is transmitted to the coronaries, the 
brain, and the kidneys, the organs that mainly suffer from 
elevated blood pressure. 
Peripheral and central blood pressure may differ signifi-
cantly due to “pressure amplification”. Typically, the dia-
stolic blood pressure does not change significantly across the 
various arterial beds; however, systolic blood pressure is 
amplified when travelling across the arterial tree, from the 
aorta to the periphery. Therefore, significant differences be-
tween the peripheral and central blood pressure are not un-
usual and might mislead therapeutic decisions that are typi-
cally based on peripheral blood pressure measurement. 
PREDICTIVE VALUE OF ARTERIAL STIFFNESS 
Accumulating data from many large longitudinal studies 
with long-term follow-up indicate that increased arterial 
stiffness, as assessed by pulse wave velocity, represents an 
independent predictor of cardiovascular morbidity and mor-
tality, as well as of all-cause mortality. The strong predictive 
value of arterial stiffness has been observed in various popu-
lations, in health and disease: in the general population [2-6], 
in elderly individuals [7-9], in subjects free of any cardio-
vascular disease not using any cardiovascular medication 
[10], in patients with impaired glucose tolerance [11], in 
diabetic patients [12], in patients with essential hypertension 
[13-16], and in patients with end-stage renal disease [17-20]. 
It has been recently shown that aortic stiffness is an inde-
pendent predictor of cardiovascular events and all-cause 
mortality even in earlier stages of chronic kidney disease and 
not only in end-stage renal failure [21]. It has been also 
shown that aortic stiffness is an independent predictor of 
functionality following an acute ischemic stroke, suggesting 
that not only the cardiovascular outcomes but also the qual-
ity of life is dependent on arterial stiffness [22]. In contrast, 
augmentation index had no independent predictive value on 
patients’ functional outcome. 
A recent meta-analysis reviewed the ability of arterial 
stiffness to predict cardiovascular events and all-cause mor-
tality [23]. The authors identified 17 longitudinal studies 
with almost 16,000 patients and a mean follow-up of 7.7 
years (2.5-19.6 years). It was found that pulse wave velocity 
was linearly associated with all studied outcomes, and any 
increase in pulse wave velocity by 1 m/sec was associated 
with approximately 15% increments in cardiovascular 
morbidity, cardiovascular mortality, and all-cause mortality. 
The pooled relative risk in patients at the highest compared 
to the lowest tertile of pulse wave velocity was 2.26 (95% 
CI: 1.89-2.70) for all cardiovascular events, 2.02 (95% CI: 
1.68-2.42) for cardiovascular mortality, and 1.90 (95% CI: 
1.61-2.24) for total mortality. 
Of note, the predictive value of pulse wave velocity was 
larger in patients with higher baseline cardiovascular risk, 
such as end-stage renal disease and hypertension (highest 
versus lowest tertile relative risk for total cardiovascular 
events: 2.81 in end-stage renal disease versus 2.46 in hyper-
tension versus 1.68 in the general population) [23]. A large 
French study in hypertensive patients suggests that the pre-
dictive value of arterial stiffness was more pronounced in 
patients at lower cardiovascular risk than in patients at 
higher cardiovascular risk [24]. Finally, a meta-regression 
analysis revealed that aortic pulse wave velocity is a stronger 
determinant of prognosis in younger patients with end-stage 
renal disease, while the predictive value of aortic pulse wave 
velocity is independent of age in hypertensive patients and in 
the general population [23].  
A very important issue is whether arterial stiffness pos-
sesses the ability to predict cardiovascular events beyond 
cardiovascular risk factors, establishing its importance in 
everyday clinical practice by re-stratifying patients’ risk. 
Available data point towards a significant additive value of 
arterial stiffness in cardiovascular risk prediction, above and 
beyond traditional risk factors, including the widely used 
Framingham and SCORE risk scores [25-28]. Evaluation of 
arterial stiffness leads to re-classification of intermediate risk 
patients to higher or lower cardiovascular risk in many cases 
[25, 28, 29]. In a recent large study of patients with moderate 
and severe chronic kidney disease, it was shown that aortic 
stiffness improves cardiovascular risk prediction beyond 
traditional cardiovascular risk factors, with a net re-
classification index of 29% [21]. 
PREDICTIVE VALUE OF AUGMENTATION INDEX 
AND CENTRAL HEMODYNAMICS 
Several longitudinal studies have assessed the impact of 
central hemodynamics on cardiovascular morbidity and mor-
tality, as well as of all-cause mortality. Relevant studies were 
performed in various populations, in health and disease: in 
elderly individuals [30], in subjects free of cardiovascular 
disease [31], in patients with essential hypertension [32], in 
patients with end-stage renal disease [33-35], and in patients 
with coronary artery disease [36-40]. 
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A recent meta-analysis calculated the predictive value of 
central blood pressure and derived central hemodynamic 
indices for cardiovascular events and all-cause mortality 
[41]. In this meta-analysis, 11 longitudinal studies were iden-
tified with more than 5,500 patients and a mean follow-up of 
45 months (3-94 months). The adjusted pooled relative risk 
of total cardiovascular events was 1.088 (95% CI: 1.040-
1.139) for a 10mmHg increase of central systolic blood pres-
sure, 1.137 (95% CI: 1.063-1.215) for a 10mmHg increase of 
central pulse pressure, and 1.318 (95% CI: 1.093-1.588) for 
a 10% increase of augmentation index. In addition, a strong 
association between augmentation index and all-cause mor-
tality was found: for a 10% increase of augmentation index 
the adjusted pooled relative risk for total mortality was 1.384 
(95% CI: 1.192-1.606). However, when central pulse pres-
sure was compared with peripheral pulse pressure, the 
pooled relative risk for cardiovascular events was marginally 
but not significantly higher.  
Of note, wave pressure was found to be higher in the at-
enolol arm compared to the amlodipine arm of the CAFÉ 
study, and predicted cardiovascular events independent of all 
other cardiovascular risk factors, while central blood pres-
sure and augmentation index failed to predict cardiovascular 
events [42]. 
PREDICTIVE VALUE OF STIFFNESS AND CEN-
TRAL HEMODYNAMICS REDUCTION 
Although a vast amount of evidence exists regarding the 
predictive value of arterial stiffness, there is a relative pau-
city of data regarding the predictive value of stiffness reduc-
tion. A study specifically addressing this issue revealed that 
patients with significant stiffness reduction had lower mor-
tality rates than patients in whom stiffness reduction was not 
achieved [43]. It has to be noted however, that this study was 
conducted in patients with end-stage renal failure and ex-
trapolation of its findings in hypertensive patients needs con-
firmation by further studies.  
Regarding the impact of central blood pressure reduction 
on cardiovascular outcomes, some indirect data point to-
wards beneficial effects of central blood pressure reduction. 
In the Anglo-Scandinavian Cardiac Outcomes Trial (AS-
COT), the combination of newer antihypertensive drugs 
(ACE-inhibitors + calcium antagonists) was found superior 
to the combination of older drugs (beta-blockers + diuretics) 
in cardiovascular outcomes, despite a rather similar office 
(peripheral) blood pressure reduction [44]. The Conduit Ar-
tery Function Evaluation (CAFE) study, a sub-study of the 
ASCOT study, showed that the combination of newer drugs 
resulted in significantly higher central blood pressure reduc-
tion than the combination of older drugs; the difference in 
central systolic blood pressure was 4.3 mmHg and the differ-
ence in central pulse pressure was 3.0 mmHg [45]. However, 
whether this difference was the reason for the better out-
comes with newer drugs or other mechanisms were also im-
plicated remains to be clarified.  
EFFECTS OF ANTIHYPERTENSIVE DRUGS ON 
ARTERIAL STIFFNESS 
Based on a vast amount of evidence, there is no doubt 
that antihypertensive treatment is associated with significant 
reductions in arterial stiffness. The comparison of active 
antihypertensive therapy with placebo shows that pulse wave 
velocity is significantly reduced with active treatment, 
whereas it remains unchanged with placebo [46-55]. The 
anticipated reduction in pulse wave velocity is about 1.0-1.5 
m/sec during long-term (>3 months) therapy, while a smaller 
reduction of 0.5-0.7 m/sec is observed acutely after admini-
stration of antihypertensive drugs [53-55]. It has to be admit-
ted however, that available data comes from studies which 
suffer from small study samples, significant differences in 
study populations, and most importantly from a relatively 
short follow-up period (usually up to 6 months).  
Antihypertensive therapy is a life-long requirement and 
the practicing physician needs to know whether the benefi-
cial effects of antihypertensive drugs on arterial stiffness are 
sustained over the years and attenuate the age-induced in-
crease in pulse wave velocity. However, it is highly unlikely 
that such information will ever become available, since it is 
unethical to use a placebo arm for long time periods in hy-
pertensive patients, given the established benefits of anti-
hypertensive therapy. There are only two patient popula-
tions, in whom there is no strong evidence regarding the 
benefits of antihypertensive therapy: very elderly patients 
(>80 years) with stage I hypertension, and young patients 
with mild hypertension and low cardiovascular risk. It would 
be interesting to design long-term clinical studies evaluating 
the effects of antihypertensive therapy on arterial stiffness 
and cardiovascular outcomes in these patient populations.  
DIFFERENCES BETWEEN ANTIHYPERTENSIVE 
DRUG CLASSES 
Pulse Wave Velocity 
Despite a widespread belief that newer antihypertensive 
agents (angiotensin receptor blockers, ACE-inhibitors, and 
calcium antagonists) are superior to other agents (diuretics, 
beta-blockers) in arterial stiffness reduction, available data 
from small, randomized clinical studies suggest that there are 
no significant differences between drug categories regarding 
their effects on arterial stiffness [56-67]. Once again, avail-
able studies suffer from the small number of participants and 
the relatively short follow-up time (less than a year).  
Since there no ethical considerations to compare anti-
hypertensive drugs in the long-term, relevant studies evaluat-
ing the effects of different classes on arterial stiffness need to 
be conducted, which have to be large, multicenter, random-
ized, and long-term (>3-4 years). It has to be noted that the 
pharmaceutical industry is not likely to support the conduc-
tion of such studies. Therefore, either authorities like the 
NIH and the European Commission, or scientific societies 
like the European and the American Society of Hyperten-
sion, or even independent groups of experts have to design, 
organize, and conduct such studies. Apart from the obvious 
financial difficulties in funding such a study, one more factor 
has to be taken also in account: only one third of patients 
(approximately) will achieve blood pressure control and re-
main in monotherapy providing clear findings, while the 
majority will require combination therapy and decrease the 
clarity of study findings. 
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Augmentation Index 
The augmentation index is a marker of the wave reflec-
tion and subsequently of the additional load on the left ven-
tricle. Most antihypertensive drugs reduce the augmentation 
index and there are no significant differences between drug 
classes [46, 48, 59, 64, 68-70], with the remarkable excep-
tion of beta-blockers. Beta-blockers not only fail to reduce 
augmentation index but actually result in increased augmen-
tation index values [64, 65, 69]. This effect of beta-blockers 
might be attributed to their effect on heart rate. It is known 
that experimentally-induced tachycardia, via right atrial pac-
ing, is associated with reductions in augmentation index; for 
every 10 beats increases in heart rate, a 5% reduction in 
augmentation index is observed [71]. It is therefore antici-
pated that beta-blockers result in augmentation index incre-
ments through bradycardia. In the CAFÉ study, a strong, 
inverse relationship between heart rate and augmentation 
index was observed, suggesting increased wave reflection at 
lower heart rate [72]. Heart rate was found to be a major 
determinant of central systolic and pulse pressure, and ad-
justment for heart rate greatly attenuated the difference in 
central blood pressure between the atenolol and amlodipine 
arm of the CAFÉ study.  
However, bradycardia by itself cannot explain the whole 
effect of beta-blockers, and several other explanations might 
be proposed: a) the failure of beta-blockers to reduce the 
wall/lumen ratio of resistant arteries, which are the main 
source of wave reflection, and b) the delay in forward’s wave 
peak due to the prolongation of ventricular ejection time 
caused by beta-blockers; therefore, the reflected wave con-
fronts higher values of the forward wave and subsequent 
increments in the augmentation index occur. 
A recent meta-analysis reported that ACE-inhibitors were 
superior to other classes of antihypertensive drugs in reduc-
ing the augmentation index [73]. However, this finding was 
ought to the superiority of ACE-inhibitors over beta-
blockers, while no significant differences were observed 
with other classes of antihypertensive drugs apart from beta-
blockers, when the comparisons were performed separately. 
Studies comparing beta-blockers to angiotensin receptor 
blockers highlight the superiority of angiotensin receptor 
blockers over beta-blockers on central hemodynamics and 
wave reflection. In a study of 21 patients with untreated hy-
pertension, atenolol was compared to eprosartan for 6 weeks. 
It was found that atenolol had less impact on central systolic 
blood pressure than eprosartan and resulted in increased 
augmentation index [74]. In a larger and long-term random-
ized study of 156 hypertensive patients, irbesartan was com-
pared to atenolol for 18 months. Atenolol therapy was asso-
ciated with an increase in augmentation index and a decrease 
of pulse pressure amplification, whereas irbesartan therapy 
exhibited beneficial effects on wave reflection [75]. 
The inferiority of beta-blockers compared to other anti-
hypertensive drug classes on augmentation index and central 
hemodynamics seems to be maintained with combination 
therapy as well. A recent large, multicenter, prospective, 
randomized study (the EXPLOR study) of 393 hypertensive 
patients compared the combination of amlodipine with either 
atenolol or valsartan for 24 weeks [76]. Both combinations 
reduced peripheral blood pressure and pulse wave velocity to 
the same extent. However, the central systolic blood pres-
sure, the augmentation index, and the heart-rate adjusted 
augmentation index were significantly more reduced with 
the valsartan combination than with the atenolol combina-
tion.  
WITHIN-CLASS DIFFERENCES 
There is no clear evidence that within-class differences 
among the various antihypertensive drug classes exist re-
garding their effects on pulse wave velocity and augmenta-
tion index. The only exception is once again beta-blockers. It 
has been shown that not all beta blockers result in augmenta-
tion index increments. 
In a retrospective study of 242 hypertensive patients it 
was found that for similar office blood pressure and aortic 
stiffness, treatment with atenolol was associated with higher 
central systolic pressure and wave reflection compared to 
treatment with either vasodilating beta-blockers (nebivolol, 
carvedilol) or angiotensin receptor blockers [77]. 
In a study of 43 obese, African-American hypertensives 
it was found that nebivolol therapy for 8 weeks resulted in 
significant improvements of arterial compliance, as assessed 
by aortic augmentation index and time to wave reflection 
[78]. 
In a randomized study of 40 untreated hypertensives, ne-
bivolol was compared to atenolol for 4 weeks [79]. Both 
agents reduced pulse wave velocity to a similar extent. How-
ever, only nebivolol reduced augmentation index and in-
creased pulse pressure amplification, suggesting a beneficial 
role in small muscular arteries, possibly due to increased 
nitric oxide bioavailability. 
Another randomized, placebo-controlled, crossover study 
of 16 naïve patients with isolated systolic hypertension com-
pared the effects of nebivolol and atenolol for 5 weeks [80]. 
It was found that both agents reduced peripheral blood pres-
sure and aortic stiffness to the same extent. However, ne-
bivolol was superior to atenolol in reducing aortic pulse 
pressure and increasing the augmentation index. 
Similar differences with atenolol have been reported with 
other beta-blockers as well. Dilevalol (an isomer of lebetalol) 
was compared to atenolol for 12 weeks in a double-blind, 
crossover, placebo-controlled study of 12 patients with es-
sential hypertension [81]. Both drugs were equally effective 
in reducing peripheral blood pressure and pulse wave veloc-
ity. However, the augmentation index was significantly 
lower with dilevalol than with atenolol. 
In a prospective, randomized, open label study of 41 hy-
pertensive patients, carvedilol was compared to atenolol for 
4 weeks [82]. Both drugs reduced peripheral and central sys-
tolic and diastolic blood pressure to a similar extent. How-
ever, the augmentation index was increased with atenolol 
and slightly decreased with carvedilol. 
From the above mentioned studies, it can be assumed that 
conventional beta-blockers (such as atenolol) do not exert 
beneficial effects on augmentation index, while vasodilating 
beta-blockers (such as nebivolol, carvedilol, and labetalol) 
share the beneficial effects of the other antihypertensive drug 
categories on augmentation index. This assumption is further 
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reinforced by a recent study comparing two conventional 
beta-blockers, such as atenolol and bisoprolol. In a large, 
prospective, randomized, open label study of 209 hyperten-
sive patients, atenolol was compared to bisoprolol (a second-
generation beta-blocker with high beta-1 selectivity) for 12 
weeks [83]. There were no significant differences between 
the two drugs in their effects on central and peripheral blood 
pressure, pulse wave velocity and augmentation index.  
FUTURE DIRECTIONS  
Accumulating data strongly point towards the ability of 
antihypertensive therapy to reduce arterial stiffness even in 
the very elderly individuals or after decades of elevated 
blood pressure. However, a critical view of available bibliog-
raphy raises several questions that need to be answered with 
future research. Such questions include: 
- Pulse wave velocity reduction appears in all patients or 
‘responders’ and ‘non-responders’ exist?  
- Are there any predictors of ‘stiffness response’? 
- Do age, blood pressure severity and duration, and base-
line blood pressure and pulse wave velocity values affect 
‘stiffness response’? 
- Which is the effect of comorbidities and concomitant 
medication? 
- Which is the definition and the clinical meaning of ‘stiff-
ness response’? 
- Is there any association of ‘stiffness response’ and rever-
sal of other target organ damage? 
- Is blood pressure reduction a pre-requisite for pulse wave 
reduction? 
- Pulse wave reduction is ought to solely blood pressure 
fall or effects beyond blood pressure reduction exist? 
- Are there any differences between antihypertensive drugs 
on ‘stiffness response’? 
- Are there within-class differences among different agents 
in the same class? 
- Does aggressive antihypertensive therapy exert better 
effects than standard therapy? 
- Are standard doses of antihypertensive drugs adequate 
for maximum ‘stiffness reduction’? What is the effect of 
low doses or supra-high doses? 
- Which are the effects of different combinations of anti-
hypertensive therapy on ‘stiffness reduction’? 
- Which is the effect of treatment discontinuation? Are 
there any ‘legacy’ effects? 
- Are the beneficial effects equally distributed in all vascu-
lar beds or differences exist? 
Providing answers for some of the above mentioned 
questions might significantly improve the management of 
hypertension and cardiovascular disease. Arterial stiffness 
and central hemodynamics represent a hot topic and research 
in this area is very intense. Technological advances might 
also be very helpful for improving our knowledge in this 
exciting topic, which has major significance from the physi-
ologic, pathophysiologic, pharmacologic and therapeutic 
point of view.  
CONCLUSIONS 
 The interest about arterial stiffness and central hemo-
dynamics in the pathophysiology and management of essen-
tial hypertension is steadily increasing over the years. A vast 
amount of evidence indicates that aortic stiffness is a strong 
and independent predictor of cardiovascular events and total 
mortality in hypertensives and other patient populations, and 
its predictive value extends beyond traditional risk factors. 
Therefore, aortic stiffness seems ready for ‘prime-time’ in 
the management of arterial hypertension. The role of central 
hemodynamics and augmentation index (a marker of re-
flected waves) requires further investigation before reaching 
everyday clinical practice. There is no doubt that antihyper-
tensive therapy reduces significantly arterial stiffness and 
central hemodynamics. However, conventional beta-blockers 
seem to be less beneficial on these parameters than the other 
antihypertensive drug categories, whereas the newer vasodi-
lating beta-blockers seem to share the benefits of the other 
antihypertensive drugs.  
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